JAMA neurology最新文献

{"title":"Cerebral White Matter Abnormality Features of Encephalitis Caused by Angiostrongylus cantonensis.","authors":"He Li, Yang Cheng, Wei Tang","doi":"10.1001/jamaneurol.2025.0058","DOIUrl":"10.1001/jamaneurol.2025.0058","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":"516-517"},"PeriodicalIF":20.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Imperative for Public Sharing of Adverse Events of Gene Therapy Trials.","authors":"Joshua L Bonkowsky, Deepa S Rajan, Florian Eichler","doi":"10.1001/jamaneurol.2024.4671","DOIUrl":"10.1001/jamaneurol.2024.4671","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":"429-430"},"PeriodicalIF":20.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Errors in the Results.","authors":"","doi":"10.1001/jamaneurol.2025.1468","DOIUrl":"10.1001/jamaneurol.2025.1468","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"82 5","pages":"529"},"PeriodicalIF":20.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sonographic Demonstration of Myopathy in Mycosis Fungoides.","authors":"David Kravitz, Erel Joffe, Alon Abraham","doi":"10.1001/jamaneurol.2025.0254","DOIUrl":"10.1001/jamaneurol.2025.0254","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":"520-521"},"PeriodicalIF":20.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.","authors":"Jennifer A Zimmer, Paul Ardayfio, Hong Wang, Rashna Khanna, Cynthia D Evans, Ming Lu, JonDavid Sparks, Scott Andersen, Steve Lauzon, Emel Serap Monkul Nery, Chakib Battioui, Staci E Engle, Alessandro Biffi, Diana Svaldi, Stephen Salloway, Steven M Greenberg, Reisa A Sperling, Mark Mintun, Dawn A Brooks, John R Sims","doi":"10.1001/jamaneurol.2025.0065","DOIUrl":"10.1001/jamaneurol.2025.0065","url":null,"abstract":"<p><strong>Importance: </strong>Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies.</p><p><strong>Objective: </strong>To characterize ARIA in participants treated with donanemab.</p><p><strong>Design, setting, and participants: </strong>These prespecified and post hoc exploratory analyses use data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials, conducted from December 2017 to December 2020 and from June 2020 to April 2023, respectively. Additional analyses are included from a stand-alone open-label addendum conducted from August 2021 through August 2023. Participants in the placebo-controlled trials and the open-label addendum aged 60 to 85 years with early symptomatic Alzheimer disease and elevated amyloid levels were included. The placebo-controlled trials, but not the addendum, had tau inclusion criteria.</p><p><strong>Interventions: </strong>Placebo-controlled trial participants were randomized 1:1 to receive placebo or donanemab, and all open-label participants received donanemab. Donanemab was administered every 4 weeks for up to 72 weeks.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were the frequency, radiographic severity, seriousness, symptoms, timing relative to donanemab treatment, and risk factors for ARIA.</p><p><strong>Results: </strong>Across 3030 total participants (placebo-controlled trials: 999 placebo participants, 984 donanemab participants; open-label addendum: 1047 donanemab participants), mean (SD) age was approximately 73.7 (6.0) years and 1684 participants (55.6%) were female. Frequencies of ARIA-edema/effusions (ARIA-E) and ARIA-microhemorrhages and hemosiderin deposition (ARIA-H) were higher with donanemab (24.4% and 31.3% in placebo-controlled trials, respectively; 19.8% and 27.2% in open-label addendum, respectively) than with placebo (1.9% and 13.0%, respectively). ARIA-E was mostly mild or moderate in severity. Serious ARIA-E was reported in 1.5% and symptomatic ARIA-E in 5.8% of donanemab-treated participants in the placebo-controlled trials. Symptoms most frequently reported with ARIA-E were headache and confusional state. In 58.3% of donanemab-treated participants with ARIA-E, the first event occurred by the third infusion (approximately month 3). Risk analysis demonstrated independent associations between ARIA-E and 6 baseline variables, including increased risk with APOE ε4 allele number, greater number of microhemorrhages, presence of cortical superficial siderosis, higher amyloid plaque, and elevated mean arterial pressure, and decreased risk with antihypertensive use.</p><p><strong>Conclusions and relevance: </strong>ARIA is an adverse event associated with donanemab treatment that requires safety monitoring. Individual ARIA risk can","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":"461-469"},"PeriodicalIF":20.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venture Capital Investment in Neurology Companies.","authors":"Ravi Dhawan, Alex B Boyle, Hithardhi Duggireddy, Margherita Rampichini, Denys Shay","doi":"10.1001/jamaneurol.2025.0137","DOIUrl":"10.1001/jamaneurol.2025.0137","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":"522-523"},"PeriodicalIF":20.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating N-of-1 Trials Into Learning Health Care Systems.","authors":"Julia E H Brown, Winston Chiong, Nora Hutchinson","doi":"10.1001/jamaneurol.2024.4674","DOIUrl":"10.1001/jamaneurol.2024.4674","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":" ","pages":"431-432"},"PeriodicalIF":20.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional Seizures-A Critical Comorbidity Overlooked in Epilepsy Research.","authors":"Mahinda Yogarajah,Barbara Dworetzky,Ley Sander","doi":"10.1001/jamaneurol.2025.0819","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0819","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"42 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia","authors":"Tobias Borgh Skillbäck, Linus Jönsson, Ingmar Skoog, Kaj Blennow, Maria Eriksdotter, Henrik Zetterberg, Silke Kern","doi":"10.1001/jamaneurol.2025.0693","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0693","url":null,"abstract":"ImportanceThe defining pathological features of Alzheimer disease (AD) may also be contributing factors in other dementias.ObjectiveTo examine the prevalence of β-amyloid (Aβ) and tau pathophysiological changes as indicated by cerebrospinal fluid biomarkers, as well as their association with clinical disease progression, across a broad range of dementias.Design, Setting, and ParticipantsIn this cross-sectional study with a duration of 12 years (October 5, 2010, to August 31, 2022), clinical data from the Swedish registry for cognitive disorders and dementia (SveDem) were merged with clinical routine biomarker measurements of the core cerebrospinal fluid biomarkers of AD: Aβ1-42, total tau (t-tau), and phosphorylated tau 181 (p-tau181). Participants were individuals with a dementia diagnosis who had a complete set of cerebrospinal fluid Aβ1-42, t-tau, and p-tau measurements registered less than 3 years after the date of diagnosis. Data were analyzed from April to November 2023.ExposuresAge, sex, and dementia diagnosis.Main Outcomes and MeasuresBiomarker profiles in relation to diagnosis and cognitive status as indicated by Mini-Mental State Examination (MMSE) scores.ResultsAmong 15 004 individuals with a dementia diagnosis in the SveDem database, 13 882 were included in this study (7328 females [53%], 6554 males [47%]; median [IQR] age, 74 [68-79] years). Apart from the AD groups (early-onset AD, 1150 [68%]; late-onset AD, 3392 [65%]; mixed AD and vascular dementia, 1038 [52%]), the dementia not otherwise specified group had the most patients (443 [25%]) with a clear AD-like biomarker profile, while Parkinson disease dementia and the frontotemporal dementia groups had the smallest shares (15 [9%] and 51 [8%], respectively). MMSE score was associated with cerebrospinal fluid Aβ1-42 in late-onset AD, vascular dementia, frontotemporal dementia, and dementia not otherwise specified; with t-tau in late-onset AD, early-onset AD, and dementia not otherwise specified; and with p-tau181 in early-onset AD.Conclusions and RelevanceAβ-related pathology is a defining feature of AD, and most patients clinically diagnosed with AD have biomarker evidence of this process, but the same is found in other dementias, although less commonly. Cerebrospinal fluid biomarker concentrations of AD-like pathology were associated with cognitive function but mainly in patients with an AD-related diagnosis (early- and late-onset AD).","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"55 5 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional Seizures-A Critical Comorbidity Overlooked in Epilepsy Research-Reply.","authors":"Churl-Su Kwon,Nathalie Jetté,Charles R Newton","doi":"10.1001/jamaneurol.2025.0822","DOIUrl":"https://doi.org/10.1001/jamaneurol.2025.0822","url":null,"abstract":"","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"47 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}